individu
infect
sar
coronaviru
sarscov
spontan
recov
without
clinic
intervent
howev
immunolog
correl
associ
patient
recoveri
current
unknown
report
sequenti
monitor
recov
patient
twoyear
period
character
tempor
chang
sarscovspecif
antibodi
respons
well
cytotox
cell
ctl
respons
found
persist
robust
antibodi
ctl
respons
studi
subject
throughout
studi
period
moder
declin
one
year
onset
symptom
also
identifi
two
potenti
major
ctl
epitop
n
protein
base
elispot
analysi
pool
peptid
howev
despit
potent
immun
respons
clinic
recoveri
peripher
lymphocyt
count
recov
patient
yet
restor
normal
level
summari
studi
first
time
character
tempor
dynam
chang
humor
ctl
respons
natur
histori
sarsrecov
individu
strongli
support
notion
high
sustain
level
immun
respons
correl
strongli
diseas
outcom
find
direct
implic
futur
design
develop
effect
therapeut
agent
vaccin
sarscov
infect
sar
sever
acut
respiratori
syndrom
seriou
respiratori
ill
caus
novel
variant
coronaviru
sarsassoci
coronaviru
sarscov
other
previous
demonstr
persist
high
level
n
proteinspecif
glycoproteinspecif
neutral
antibodi
nab
respons
first
sever
week
infect
correl
diseas
outcom
howev
littl
known
magnitud
longev
humor
ctl
respons
prolong
recoveri
studi
longterm
chang
humor
ctl
respons
recov
patient
verifi
earlier
find
shortterm
followup
also
establish
correl
protect
gener
futur
vaccin
candid
start
march
enrol
sequenti
follow
patient
diagnos
recov
sarscov
infect
accord
clinic
criteria
releas
world
health
organ
http
wwwwhointcsrsarscasedefinitionen
sequenti
blood
sampl
collect
month
onset
symptom
enrol
patient
depart
infecti
diseas
peke
union
medic
colleg
hospit
beij
guidelin
ethic
review
committe
hospit
recov
patient
defin
free
acut
ill
high
bodi
temperatur
dri
cough
lightwhit
sputum
short
breath
hypoxia
airspac
consolid
lung
approxim
month
onset
symptom
definit
seroposit
sarscov
lysat
least
two
consecut
occas
clinic
recov
patient
regain
normal
bodi
temperatur
experi
cough
chest
pain
normal
chest
radiograph
normal
pulmonari
function
averag
age
patient
male
femal
particip
patient
antibodi
antigen
neg
cytomegaloviru
cmv
epsteinbarr
viru
ebv
purpos
comparison
blood
sampl
also
obtain
normal
healthi
age
match
individu
averag
age
individu
male
femal
use
flow
cytometri
first
studi
sequenti
chang
absolut
number
total
lymphocyt
lymphocyt
b
lymphocyt
natur
killer
nk
cell
two
year
followup
compar
normal
healthi
control
show
fig
recov
patient
clearli
experienc
two
distinct
phase
cell
restor
peripher
blood
initi
rapid
phase
cell
popul
studi
first
month
onset
symptom
follow
signific
slower
phase
subsequ
month
first
month
averag
increas
cell
popul
studi
high
per
month
mean
absolut
total
lymphocyt
lymphocyt
b
lymphocyt
nk
cell
increas
cellsmm
cell
mm
cellsmm
cellsmm
cellsmm
cellsmm
respect
rapid
phase
lymphocyt
recoveri
reminescinet
report
crosssect
studi
recov
sar
patient
first
week
onset
symptom
other
shown
previous
initi
rapid
phase
peripher
lymphocyt
recoveri
usual
coincid
improv
clinic
condit
sar
patient
first
month
howev
percent
increas
drop
per
month
case
remain
unchang
slightli
decreas
previou
time
point
fig
distinct
rate
lymphocyt
recoveri
two
phase
like
reflect
differ
mechan
lymphocyt
regener
prolifer
distribut
vivo
furthermor
except
b
lymphocyt
mean
absolut
number
total
lymphocyt
lymphocyt
nk
cell
month
onset
symptom
remain
statist
differ
normal
healthi
agematch
control
find
suggest
complet
restor
peripher
lymphocyt
may
requir
longer
period
peripher
lymphocyt
reduct
sar
patient
perman
despit
recoveri
clinic
manifest
sarscov
infect
longer
followup
patient
need
address
two
possibl
studi
sequenti
chang
humor
respons
sarscov
use
previous
publish
elisabas
pseudotyp
retrovirusbas
neutral
system
first
analyz
tempor
chang
total
serum
igg
specif
sarscov
use
commerci
avail
elisa
assay
huada
comp
beij
china
base
purifi
whole
viru
lysat
shown
fig
initi
increas
total
igg
month
onset
symptom
follow
gradual
decreas
ensu
period
fact
much
decreas
observ
month
onset
symptom
signific
chang
found
afterward
fig
addit
also
character
tempor
chang
n
proteinspecif
antibodi
glycoproteinspecif
neutral
antibodi
nab
respons
patient
experi
conduct
serum
sampl
two
differ
dilut
fig
depict
tempor
chang
n
proteinspecif
antibodi
followup
base
n
proteinbas
elisa
found
antibodi
n
protein
detect
throughout
entir
period
studi
within
first
month
onset
symptom
n
proteinspecif
antibodi
remain
rel
high
although
clear
trend
decreas
time
signific
drop
titer
month
onset
symptom
dramat
chang
afterward
fig
trend
chang
n
proteinspecif
antibodi
also
observ
experi
conduct
dilut
fig
regard
glycoproteinspecif
nab
use
previous
publish
pseudotyp
retrovir
system
glycoprotein
surfac
virion
protein
encapsul
within
consist
observ
nprotein
specif
antibodi
high
sustain
level
glycoproteinspecif
nab
detect
throughout
entir
phase
studi
fig
dilut
sampl
potent
neutral
activ
capabl
neutral
least
input
virion
median
level
activ
larger
fig
also
trend
decreas
glycoproteinspecif
nab
titer
time
dramat
drop
found
month
found
n
proteinspecif
antibodi
lastli
trend
chang
glycoproteinspecif
nab
also
observ
experi
conduct
dilut
fig
remain
seen
whether
level
sarscovspecif
antibodi
remain
unchang
continu
declin
month
followup
studi
sequenti
chang
ctl
respons
sarscov
use
elispotbas
techniqu
quantifi
number
infc
releas
cell
peripher
blood
peptid
pool
cover
entir
n
protein
deriv
urbani
strain
peptid
pool
made
peptid
amino
acid
residu
length
overlap
amino
acid
residu
peptid
pool
obtain
biodefens
emerg
infect
resourc
repositori
nation
institut
health
nih
unit
state
http
wwwbeiresourcesorglistingindexcfm
first
studi
sequenti
chang
total
number
infc
releas
cell
express
spot
form
cell
sfc
per
million
pbmc
peripher
blood
month
onset
symptom
fig
show
averag
number
infc
releas
cell
detect
month
onset
symptom
observ
antibodi
respons
detect
level
ctl
respons
found
throughout
studi
period
although
clear
trend
decreas
time
fig
identifi
major
epitop
recogn
ctl
peptid
divid
peptid
pool
crossbroad
fashion
vs
fig
upper
panel
intens
magnitud
ctl
respons
peptid
pool
present
either
total
number
sfc
per
million
pbmc
percent
sampl
detect
level
infc
releas
cell
fig
fig
summar
result
sampl
test
four
peptid
pool
name
found
preferenti
recogn
recov
sar
patient
fig
crossbroad
analysi
found
potenti
two
major
ctl
epitop
n
protein
one
locat
within
region
cover
peptid
cover
peptid
fig
upper
panel
peptid
correspond
amino
acid
sequenc
masgggetalalllldrlnqleskv
posit
n
protein
wherea
peptid
match
sequenc
twltyhgaiklddkdpqfkdnvil
posit
fig
lower
panel
serotyp
mhc
class
ii
found
predomin
among
studi
popul
tabl
futur
work
would
requir
fine
map
actual
ctl
epitop
two
region
associ
particular
serotyp
mhc
class
report
extend
earli
studi
sequenti
monitor
recov
sar
patient
period
character
tempor
chang
humor
ctl
respons
sarscov
shown
first
time
recov
patient
persist
robust
bind
well
neutral
antibodi
ctl
respons
throughout
studi
period
moder
declin
one
year
onset
symptom
particular
glycoproteinspecif
nab
respons
persist
high
recov
patient
even
month
onset
symptom
high
sustain
level
sarscovspecif
immun
respons
patient
clear
distinct
found
patient
succumb
diseas
suggest
antibodi
respons
like
play
import
role
determin
ultim
diseas
outcom
sarscov
infect
patient
addit
also
identifi
two
potenti
major
ctl
epitop
n
protein
base
elispot
analysi
peptid
futur
work
requir
identifi
actual
epitop
greater
detail
howev
despit
potent
immun
respons
clinic
recoveri
peripher
lymphocyt
count
recov
patient
yet
restor
normal
level
find
suggest
complet
restor
peripher
lymphocyt
may
requir
longer
period
time
lymphocyt
destruct
sarscov
infect
perman
repair
partial
summari
studi
first
time
character
tempor
dynam
chang
humor
ctl
respons
natur
histori
sarsrecov
individu
strongli
support
notion
high
sustain
level
immun
respons
correl
strongli
diseas
outcom
strongli
believ
find
direct
implic
design
develop
therapeut
vaccin
sarscov
infect
replic
thirti
sar
patient
enrol
march
continu
follow
sinc
diagnos
recov
sarscov
infect
accord
clinic
criteria
releas
world
health
organ
http
wwwwhoint
csrsarscasedefinitionen
sequenti
blood
sampl
collect
inform
consent
approv
ethic
review
committe
depart
infecti
diseas
peke
union
medic
colleg
hospit
beij
averag
age
patient
male
femal
purpos
comparison
blood
sampl
also
obtain
normal
healthi
age
match
individu
averag
age
individu
male
femal
flow
cytometr
analys
variou
lymphocyt
popul
peripher
blood
use
previous
publish
protocol
analysi
bind
antibodi
whole
sarscov
lysat
n
protein
glycoproteinspecif
neutral
antibodi
nab
conduct
previous
report
elispot
assay
perform
use
commerci
avail
kit
diaclon
franc
accord
manufactur
introduct
peptid
pool
cover
entir
n
protein
urbani
strain
use
stimul
patient
peripher
blood
mononuclear
cell
peptid
pool
made
peptid
amino
acid
residu
length
overlap
amino
acid
residu
peptid
obtain
biodefens
emerg
infect
resourc
repositori
nation
institut
health
nih
unit
state
http
wwwbeiresourcesorglistingindexcfm
student
test
analysi
use
determin
signific
result
valu
p
indic
statist
signific
